Kurma Partners

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€215m

Latest public closing

23 Apr 2026

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

European venture capital firm focused on healthcare and life-sciences innovation.

Focus: Therapeutics, diagnostics, digital health, medtech and drug development, from company creation through growth

23 April 2026: Kurma Biofund IV reached final close at €215m (company press release).